Characteristics Study population (N = 65) Complete responders of CSD (N = 51) Non-responders of CSD (N=14) p value* (comparison between CSD responders and non-responders)
Age (mean ± SD) 50±18 49±17 53±20 0.307
Gender (Male:Female) 50:15 39:12 11:3 0.870
Hypertension 23 (35.4%) 16 (31.4%) 7(50%) 0.200
Etiology of VT (ICMP:NICMP) 30:35 22:29 8:6 0.356
Diabetes Mellitus 12(18.5%) 8 (15.7%) 4(28.6%) 0.291
Hyperlipidemia 15 (23.1%) 10 (19.6%) 5(35.7%) 0.209
Atrial Fibrillation 7 (10.8%) 5 (9.8%) 2(14.3%) 0.634
LVEF 0.28±0.13 0.29±0.13 0.24±0.12 0.136
NYHA status prior to CSD I II III IV 3 (4.6%) 20 (30.8%) 35 (53.8%) 7 (10.8%) 5 (9.8%) 14(27.5%) 29(56.9%) 3(5.9%) 1 (7.1%) 0 (0%) 6 (42.9%) 7(50%)
0.001
Devices implanted prior to CSD No AICD AICD CRT-D 8(12.3%) 51(78.5%) 6 (9.2%) 7(13.7%) 40(78.4%) 4(7.8%) 1(7.1%) 11(78.6%) 2(14.3%)
0.356
Morphologies of VT Monomorphic Pleomorphic Polymorphic 19(29.2%) 38 (58.5%) 8 (12.3%) 16(31.4%) 28(54.9%) 7(13.7%) 3(21.4%) 10(71.4%) 1(7.1%)
0.305
Radiofrequency ablation attempted prior to CSD 14 (21.5%) 11(21.6%) 4 (28.6%) 0.585
Medications Amiodarone B Blockers 55(83.3%) 41(62.1%) 44 (86.3%) 33 (64.7%) 11(78.6%) 2(21.4%) 0.483 0.606
Type of CSD Unilateral (left) Bilateral 5 (7.7%) 60 (92.3%) 4(7.8%) 47(92.2%) 1(7.1%) 13(92.9%)
0.931